Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.49 |
| ▸ | CPT1A | P50416 | 8/20 | 0.48 |
| ▸ | CPT1B | Q92523 | 8/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349847 | 0.87 | PTGDR2 (0.52) | PTGDR2CYP3A4PTGDRCPT1ACPT1B | |
| SCHEMBL349708 | 0.85 | CYP3A4 (0.56) | PTGDR2CYP3A4PTGDRCPT1ACPT1B | |
| SCHEMBL348006 | 0.84 | CYP3A4 (0.69) | PTGDR2CYP3A4PTGDRALDH1A1 | |
| SCHEMBL1568694 | 0.84 | PTGDR2 (0.53) | PTGDR2CYP3A4PTGDRCPT1ACPT1B | |
| SCHEMBL349453 | 0.82 | CYP3A4 (0.57) | PTGDR2CYP3A4CPT1ACPT1B | |
| SCHEMBL349851 | 0.82 | CYP3A4 (0.74) | PTGDR2CYP3A4PTGDRCPT1ACPT1B | |
| SCHEMBL347029 | 0.81 | CYP3A4 (0.56) | PTGDR2CYP3A4CPT1ACPT1BALDH1A1 | |
| SCHEMBL349124 | 0.81 | CYP3A4 (0.56) | PTGDR2CYP3A4CPT1ACPT1BALDH1A1 | |
| SCHEMBL1009931 | 0.81 | PTGDR2 (0.55) | PTGDR2CYP3A4PTGDRCPT1ACPT1B | |
| SCHEMBL349712 | 0.80 | CYP3A4 (0.56) | PTGDR2CYP3A4CPT1ACPT1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1441/4885PTGDR 1/4885 |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1441/4885PTGDR 1/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1441/4885PTGDR 1/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1367/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.